The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Economic evaluation of work productivity gains associated with ribociclib (RIB) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2-) early breast cancer (EBC) in the United States.
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer; Sanofi
 
Joseph Sparano
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; General Dynamics Information Technology (GDIT); Lyell Immunopharma; Novartis; NSABP Foundation; Pfizer; Seagen
Research Funding - Olema Pharmaceuticals (Inst)
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Vk Gadi
Stock and Other Ownership Interests - 3rdEyeBio; Emerging Markets Cancer Ignition Fund; New Equilibrium Biosciences; Novilla; Phoenix Molecular Designs; Sengine precision medicine; Tahoma Therapeutics
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Hologic; Novartis; Puma Biotechnology; Seagen/Pfizer; Stemline Therapeutics
Speakers' Bureau - Hologic; Puma Biotechnology; Seagen; Stemline Therapeutics
Research Funding - Agendia (Inst); Illumina (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Puma Biotechnology; Seagen
 
Jason Shafrin
Research Funding - Novartis
 
Xinglei Chai
Research Funding - Abbvie
 
Fan Yang
No Relationships to Disclose
 
Zheng-Yi Zhou
Other Relationship - Analysis Group
 
Vaidyanathan Ganapathy
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Corinth Auld
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Gary Sopher
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Emma Alexander
Employment - Novartis Ireland Ltd.
 
Vamsi Bollu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Louis Garrison
No Relationships to Disclose